Advanced Interventions Service, Area 7, Level 6, South Block, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.
J Neurol Neurosurg Psychiatry. 2011 Jun;82(6):594-600. doi: 10.1136/jnnp.2010.217901. Epub 2010 Dec 15.
There is very limited evidence for the efficacy of any specific therapeutic intervention in chronic, treatment refractory major depression. Thermal anterior capsulotomy (ACAPS) is a rarely performed but established therapeutic procedure for this patient group. While benefit has been claimed, previous ACAPS reports have provided limited information. Detailed prospective reporting of therapeutic effects and side effects is required.
To report a prospective study of therapeutic effect, mental status, quality of life, social functioning and neurocognitive functioning in individuals with chronic treatment refractory major depression, treated with ACAPS.
A prospective case series of 20 patients treated with ACAPS between 1992 and 1999 were reassessed at a mean follow-up of 7.0±3.4 years. Data were collected preoperatively and at long term follow-up. Structural MRI was performed in 14 participants.
According to a priori criteria, at long term follow-up, 50% were classified as 'responders' and 40% as 'remitters'. Fifty-five per cent were classified as 'improved'; 35% were 'unchanged'; and 10% had 'deteriorated'. Neurocognitive and personality testing were not significantly different at follow-up. A trend towards improvement in some aspects of executive neuropsychological functioning was observed. Significant adverse effects were infrequent and there were no deaths.
ACAPS may represent an effective intervention for some patients with chronic, disabling, treatment refractory major depression that has failed to respond to other therapeutic approaches. The adverse effect burden within this population was modest, with no evidence of generalised impairment of neurocognitive functioning.
对于慢性、治疗抵抗性重度抑郁症,任何特定治疗干预的疗效都只有非常有限的证据支持。热前囊切开术(ACAPS)是一种针对该患者群体的罕见但已确立的治疗方法。虽然有疗效的说法,但以前的 ACAPS 报告提供的信息有限。需要详细的前瞻性报告治疗效果和副作用。
报告一项对接受 ACAPS 治疗的慢性治疗抵抗性重度抑郁症患者的治疗效果、精神状态、生活质量、社会功能和神经认知功能的前瞻性研究。
1992 年至 1999 年间,对 20 例接受 ACAPS 治疗的患者进行了前瞻性病例系列研究,平均随访 7.0±3.4 年。在术前和长期随访时收集数据。对 14 名参与者进行了结构性 MRI 检查。
根据预先确定的标准,在长期随访时,50%的患者被归类为“应答者”,40%的患者被归类为“缓解者”。55%的患者被归类为“改善”;35%的患者“无变化”;10%的患者“恶化”。神经认知和人格测试在随访时没有显著差异。观察到执行神经心理功能某些方面的改善趋势。不良事件的发生率较低,没有死亡病例。
ACAPS 可能代表一种有效的治疗方法,适用于一些对其他治疗方法无反应的慢性、致残、治疗抵抗性重度抑郁症患者。该人群的不良反应负担较轻,没有证据表明神经认知功能普遍受损。